An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Pegadricase (Primary) ; SEL 212 (Primary) ; Sirolimus (Primary)
- Indications Gout; Gouty arthritis
- Focus Adverse reactions
- Sponsors Selecta Biosciences
- 05 Oct 2017 According to a Selecta Biosciences media release, initial data will be presented at the American College of Rheumatology Annual Meeting (ACR 2017).
- 03 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Mar 2018.
- 03 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History